Cargando…
Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018
BACKGROUND: Primary drug-resistant tuberculosis (DR-TB) has contributed to a significant health and economic burden on a global scale, especially in China. we sought to estimate epidemiological characteristics of primary DR-TB in China from 2004 to 2018. METHODS: Eleven thousand four hundred sixty-s...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798379/ https://www.ncbi.nlm.nih.gov/pubmed/31627757 http://dx.doi.org/10.1186/s12931-019-1199-3 |
_version_ | 1783460025106169856 |
---|---|
author | Song, Wan-mei Li, Yi-fan Ma, Xiao-bin Liu, Jin-yue Tao, Ning-ning Liu, Yao Zhang, Qian-yun Xu, Ting-ting Li, Shi-jin Yu, Chun-Bao Gao, Lei Cui, Liang-liang Li, Huai-chen |
author_facet | Song, Wan-mei Li, Yi-fan Ma, Xiao-bin Liu, Jin-yue Tao, Ning-ning Liu, Yao Zhang, Qian-yun Xu, Ting-ting Li, Shi-jin Yu, Chun-Bao Gao, Lei Cui, Liang-liang Li, Huai-chen |
author_sort | Song, Wan-mei |
collection | PubMed |
description | BACKGROUND: Primary drug-resistant tuberculosis (DR-TB) has contributed to a significant health and economic burden on a global scale, especially in China. we sought to estimate epidemiological characteristics of primary DR-TB in China from 2004 to 2018. METHODS: Eleven thousand four hundred sixty-seven newly diagnosed and 1981 retreated TB cases with drug susceptibility data were included. Chi-Square test for trends, linear regression, a joinpoint regression model and temporal trend in proportions of the different resistance patterns were carried out. RESULTS: The proportion of primary DR-TB and mono-resistant TB (MR-TB) in China had reduced by more than 12% since 2004, and were 21.38%, 13.35% in 2018 respectively. Among primary DR-TB cases (2173,18.95%), the percentage of multiresistant TB (MDR-TB, from 5.41 to 17.46%), male (from 77.03 to 84.13%), cavity (from 13.51 to 43.92%), rifampicin(RFP)-resistant TB (from 8.11 to 26.98%), streptomycin(SM)-resistant TB (from 50.00 to 71.43%) increased significantly (P < 0.05). On the contrary, the proportion of female, non-cavity, isoniazide(INH)-resistant TB (from 55.41 to 48.15%) and MR-TB (from 82.43 to 62.43%) decreased significant (P < 0.05). The primary drug resistance rate among female, cavity, smoking, drinking, 15 to 44 year-old TB subgroups increased by 0.16, 6.24, 20.95, 158.85, 31.49%, respectively. The percentage of primary DR-TB, RFP-resistant TB dropped significantly during 2004–2007 in Joinpoint regression model. CONCLUSION: The total rate of drug resistance among new TB cases showed a downward trend in Shandong, China, from 2004 to 2018. Primary drug resistance patterns were shifting from female, non-cavity, INH-resistant TB, and MR-TB groups to male, cavity, RFP/SM-resistant TB, and MDR-TB groups. Considering the rising drug resistance rate among some special population, future control of primary DR-TB in China may require an increased focus on female, cavity, smoking, drinking, or 15 to 44 year-old TB subgroups. |
format | Online Article Text |
id | pubmed-6798379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-67983792019-10-21 Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018 Song, Wan-mei Li, Yi-fan Ma, Xiao-bin Liu, Jin-yue Tao, Ning-ning Liu, Yao Zhang, Qian-yun Xu, Ting-ting Li, Shi-jin Yu, Chun-Bao Gao, Lei Cui, Liang-liang Li, Huai-chen Respir Res Research BACKGROUND: Primary drug-resistant tuberculosis (DR-TB) has contributed to a significant health and economic burden on a global scale, especially in China. we sought to estimate epidemiological characteristics of primary DR-TB in China from 2004 to 2018. METHODS: Eleven thousand four hundred sixty-seven newly diagnosed and 1981 retreated TB cases with drug susceptibility data were included. Chi-Square test for trends, linear regression, a joinpoint regression model and temporal trend in proportions of the different resistance patterns were carried out. RESULTS: The proportion of primary DR-TB and mono-resistant TB (MR-TB) in China had reduced by more than 12% since 2004, and were 21.38%, 13.35% in 2018 respectively. Among primary DR-TB cases (2173,18.95%), the percentage of multiresistant TB (MDR-TB, from 5.41 to 17.46%), male (from 77.03 to 84.13%), cavity (from 13.51 to 43.92%), rifampicin(RFP)-resistant TB (from 8.11 to 26.98%), streptomycin(SM)-resistant TB (from 50.00 to 71.43%) increased significantly (P < 0.05). On the contrary, the proportion of female, non-cavity, isoniazide(INH)-resistant TB (from 55.41 to 48.15%) and MR-TB (from 82.43 to 62.43%) decreased significant (P < 0.05). The primary drug resistance rate among female, cavity, smoking, drinking, 15 to 44 year-old TB subgroups increased by 0.16, 6.24, 20.95, 158.85, 31.49%, respectively. The percentage of primary DR-TB, RFP-resistant TB dropped significantly during 2004–2007 in Joinpoint regression model. CONCLUSION: The total rate of drug resistance among new TB cases showed a downward trend in Shandong, China, from 2004 to 2018. Primary drug resistance patterns were shifting from female, non-cavity, INH-resistant TB, and MR-TB groups to male, cavity, RFP/SM-resistant TB, and MDR-TB groups. Considering the rising drug resistance rate among some special population, future control of primary DR-TB in China may require an increased focus on female, cavity, smoking, drinking, or 15 to 44 year-old TB subgroups. BioMed Central 2019-10-18 2019 /pmc/articles/PMC6798379/ /pubmed/31627757 http://dx.doi.org/10.1186/s12931-019-1199-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Song, Wan-mei Li, Yi-fan Ma, Xiao-bin Liu, Jin-yue Tao, Ning-ning Liu, Yao Zhang, Qian-yun Xu, Ting-ting Li, Shi-jin Yu, Chun-Bao Gao, Lei Cui, Liang-liang Li, Huai-chen Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018 |
title | Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018 |
title_full | Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018 |
title_fullStr | Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018 |
title_full_unstemmed | Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018 |
title_short | Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018 |
title_sort | primary drug resistance of mycobacterium tuberculosis in shandong, china, 2004–2018 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798379/ https://www.ncbi.nlm.nih.gov/pubmed/31627757 http://dx.doi.org/10.1186/s12931-019-1199-3 |
work_keys_str_mv | AT songwanmei primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT liyifan primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT maxiaobin primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT liujinyue primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT taoningning primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT liuyao primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT zhangqianyun primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT xutingting primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT lishijin primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT yuchunbao primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT gaolei primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT cuiliangliang primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT lihuaichen primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 |